Latest Information Update: 15 Dec 2010
At a glance
- Originator POZEN
- Class Antiulcers
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 15 Dec 2010 No development reported - Phase-I for Gastro-oesophageal reflux in USA (PO)
- 20 Mar 2009 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)